Serpina1 iRNA compositions and methods of use thereof

US11725207B2 · kind B2 · utility

Assignee

• Alnylam Pharmaceuticals, Inc. · US

Inventors

• Mark K. Schlegel · Cambridge, US
• Maja Janas · Cambridge, US
• Vasant Jadhav · Cambridge, US
• Donald C. Foster · Lake Forest Park, US
• Muthiah Manoharan · Carlsbad, US
• Kallanthottathil G. Rajeev · Wayland, US
• Alexander V. Kel'in · Swampscott, US
• Klaus Charisse · Acton, US
• Jayaprakash K. Nair · Cambridge, US
• Martin Maier · Cambridge, US
• Shigeo Matsuda · Cambridge, US
• Muthusamy Jayaraman · Cambridge, US
• Alfica Sehgal · Cambridge, US
• Christopher BROWN · Cambridge, US
• Kevin Fitzgerald · Brookline, US
• Stuart Milstein · Cambridge, US

Key dates

• Filing date: Mar 8, 2021
• Grant date: Aug 15, 2023
• Expiry date: Jul 16, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2310/351
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the Serpina1 gene, and methods of using such RNAi agents to inhibit expression of Serpina1 and methods of treating subjects having a Serpina1 associated disease, such as a liver disorder.